Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Biomed Res Int ; 2021: 8835891, 2021.
Article in English | MEDLINE | ID: mdl-33763487

ABSTRACT

BACKGROUND: Pregabalin has received wide clinical attention as a new type of analgesic. We undertake a systematic review and meta-analysis to evaluate the effect of pregabalin on postoperative pain in patients undergoing cardiac surgery. METHODS: We searched PubMed, Embase, and Cochrane Library (from inception to July 2020) for eligible studies. The primary outcomes were the total morphine consumption at 24 h. A secondary outcome was intraoperative fentanyl consumption, extubation time postoperative, and length of stay in hospital. We calculated pooled weighted mean difference (WMD) or odds ratio (OR) and 95% CIs using random- or fixed-effects models. RESULTS: Seven trials involving 463 patients were listed. Meta-analysis showed that the total morphine consumption at 24 h in the pregabalin group was significantly less than the control group (WMD: -5.44, 95% CI: -10.42-0.46, P = 0.03). We found that there is no significant difference between the two groups in intraoperative fentanyl consumption. Compared with the control group, the length of stay in hospital in the pregabalin group was significantly shorter (WMD = -0.87, 95% CI: -1.42-0.32, P = 0.002). And we found that there were no significant differences between the two groups in extubation time (WMD: 17.24, 95% CI: -24.36-58.84, P = 0.42). CONCLUSIONS: Oral pregabalin for cardiac surgery patients can effectively reduce the patient's 24-hour morphine consumption after surgery, shorten the patient's hospital stay, and is more conducive to early postoperative recovery.


Subject(s)
Cardiac Surgical Procedures , Length of Stay , Pain, Postoperative/drug therapy , Pregabalin/therapeutic use , Humans , Randomized Controlled Trials as Topic
3.
Medicine (Baltimore) ; 99(31): e21397, 2020 Jul 31.
Article in English | MEDLINE | ID: mdl-32756133

ABSTRACT

OBJECTIVES: To evaluate the efficacy and safety of caudal dexmedetomidine in pediatric caudal anesthesia (CA). METHODS: We searched PubMed, Embased, and Cochrane Library (from inception to June 2019) for eligible studies. The primary outcomes were the time to first analgesia, time of postoperative eye opening, intraoperative endtidal sevoflurane concentration, and postoperative sedation score. We calculated pooled risk ratios (RR) and 95% CIs using random- or fixed-effects models. RESULTS: Thirteen trials involving 793 patients were found. Meta-analysis showed that the time to first rescue pain medication and the time from the end of anesthesia to eye opening in the CA+dexmedetomidine group were significantly longer than in the CA group (P < .00001). The intraoperative end-tidal sevoflurane concentration in the CA+dexmedetomidine group was significantly decreased (P < .00001). Dexmedetomidine appeared to increase the rate of bradycardia in the CA+dexmedetomidine group (P = .04). Additionally, the sedation score in the CA+ dexmedetomidine group was significantly higher at 2 hours after the operation compared with the CA group (P < .00001 at 2 hours). CONCLUSIONS: Caudally administered dexmedetomidine is a good alternative for prolonging postoperative analgesia with less pain, decreased intraoperative end-tidal sevoflurane concentration, and full postoperative sedation.


Subject(s)
Anesthesia, Caudal , Dexmedetomidine/administration & dosage , Hypnotics and Sedatives/administration & dosage , Randomized Controlled Trials as Topic , Child , Humans , Pain, Postoperative/prevention & control
4.
J Knee Surg ; 31(7): 654-663, 2018 Aug.
Article in English | MEDLINE | ID: mdl-28895645

ABSTRACT

The use of tranexamic acid (TXA) during primary total knee arthroplasty (TKA) is well documented. However, considering the potential side effects, including deep vein thrombosis (DVT) and pulmonary embolism (PE), the ideal route of administration remains controversial. Therefore, we performed a meta-analysis to compare the efficacy of topical versus intravenous TXA and explore the most effective regimen in patients undergoing primary TKA. We conducted a systematic literature search in PubMed, Embase, and the Cochrane database through July 2016 to identify randomized controlled trials (RCTs) evaluating the efficacy and safety of topical and intravenous TXA in primary TKA. We assessed the risk of bias using the Cochrane Collaboration's tool. We assessed the quality of evidence using the GRADE profiler software. A total of 15 RCTs including 1,240 participants met the inclusion criteria. We found no statistically significant difference between topical and intravenous TXA in terms of transfusion rate (p = 0.75), total blood loss (p = 0.51), total drain output (p = 0.60), maximum hemoglobin drop (p = 0.24), length of stay (p = 0.08), and thromboembolic complications (p = 0.73). Subgroup analyses showed that compared with 1 g topical TXA, 2 g topical TXA was more effective to reduce blood transfusion rate and total blood loss, and did not increase thromboembolic complications. We also found three times intravenous TXA was more effective than one time of intravenous TXA to reduce blood transfusion rate and total blood loss without increasing of thromboembolic complications. Topical TXA had a similar efficacy to intravenous TXA in reducing blood transfusion and blood loss, and did not increase the risk of thromboembolic complications in primary TKA. Besides, the current meta-analysis suggested that three times of intravenous TXA is efficient and safe. We also recommended 2 g topical TXA instead of 1 g topical TXA because it was more efficient to reduce blood transfusion rate and total blood loss and did not increase thromboembolic complications.


Subject(s)
Antifibrinolytic Agents/administration & dosage , Arthroplasty, Replacement, Knee/adverse effects , Blood Loss, Surgical/prevention & control , Blood Transfusion , Postoperative Hemorrhage/prevention & control , Tranexamic Acid/administration & dosage , Administration, Intravenous , Administration, Topical , Antifibrinolytic Agents/adverse effects , Clinical Protocols , Humans , Postoperative Hemorrhage/etiology , Pulmonary Embolism/chemically induced , Pulmonary Embolism/prevention & control , Randomized Controlled Trials as Topic , Thromboembolism/chemically induced , Thromboembolism/prevention & control , Tranexamic Acid/adverse effects , Venous Thrombosis/chemically induced , Venous Thrombosis/prevention & control
5.
Biomed Res Int ; 2017: 1203538, 2017.
Article in English | MEDLINE | ID: mdl-28286753

ABSTRACT

Background. We undertake a systematic review and meta-analysis to evaluate the effect of preoperative hypertension and preoperative antihypertensive medication to postoperative atrial fibrillation (POAF) in patients undergoing cardiac surgery. Methods. We searched PubMed, Embase, and Cochrane Library (from inception to March 2016) for eligible studies. The outcomes were the effects of preoperative hypertension, preoperative calcium antagonists regimen, preoperative ACE inhibitors regimen, and preoperative beta blocking agents regimen with POAF. We calculated pooled risk ratios (OR) and 95% CIs using random- or fixed-effects models. Results. Twenty-five trials involving 130087 patients were listed. Meta-analysis showed that the number of preoperative hypertension patients in POAF group was significantly higher (P < 0.05), while we found that there are no significant differences between two groups in Asia patients by subgroup analysis, which is in contrast to other outcomes. Compared with the Non-POAF group, the number of patients who used calcium antagonists and ACE inhibitors preoperatively in POAF group was significantly higher (P < 0.05). And we found that there were no significant differences between two groups of preoperative beta blocking agents used (P = 0.08). Conclusions. Preoperative hypertension and preoperative antihypertensive medication in patients undergoing cardiac operations seem to be associated with higher risk of POAF.


Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Atrial Fibrillation , Calcium Channel Blockers/therapeutic use , Cardiac Surgical Procedures , Hypertension , Preoperative Care , Atrial Fibrillation/classification , Atrial Fibrillation/physiopathology , Atrial Fibrillation/therapy , Clinical Trials as Topic , Female , Humans , Hypertension/complications , Hypertension/physiopathology , Hypertension/therapy , Male
6.
J Knee Surg ; 30(9): 854-862, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28114702

ABSTRACT

Partial and total meniscectomies are the most common treatments for patients with discoid lateral meniscus (DLM). We conducted this study to quantitatively assess and compare the outcomes of partial and total meniscectomies for DLM. We also assessed whether the outcomes differed by the type of DLM, duration of follow-up, and age of patients. We searched PubMed, Embase, and the Cochrane database to identify relevant studies that reported outcomes, including Ikeuchi grade, the International Knee Documentation Committee (IKDC) Subjective Knee score, Lysholm score, or failure rate, in patients who underwent partial and total meniscectomies. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for dichotomous outcomes, whereas mean difference and 95% CIs were calculated for continuous outcomes. Fifteen studies met the inclusion criteria. The overall rate of excellent (E) or good (G) postoperatively was 85.5% (95% CI: 79.5-91.5%). The E or G rate of partial meniscectomy was significantly higher than that of total meniscectomy (OR= 1.97, 95% CI: 1.03-3.75, p = 0.038). Besides, patients younger than 20 years had a significantly higher E or G rate than those older than 20 years. (OR = 3.12, 95% CI: 1.18-8.23, p = 0.022). We also found the E or G rate tended to decrease from short- to long-term follow-up. Our systematic review and meta-analysis showed that that partial meniscectomy could achieve better outcomes compared with total meniscectomy for DLM patients.


Subject(s)
Meniscectomy , Menisci, Tibial/abnormalities , Menisci, Tibial/surgery , Humans
7.
Arthroscopy ; 33(3): 659-670.e1, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28012636

ABSTRACT

PURPOSE: To use meta-analysis techniques to evaluate the efficacy and safety of platelet-rich plasma (PRP) injections for the treatment knee of osteoarthritis (OA). METHODS: We performed a systematic literature search in PubMed, Embase, Scopus, and the Cochrane database through April 2016 to identify Level I randomized controlled trials that evaluated the clinical efficacy of PRP versus control treatments for knee OA. The primary outcomes were Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and function scores. The primary outcomes were compared with their minimum clinically important differences (MCID)-defined as the smallest difference perceived as important by the average patient. RESULTS: We included 10 randomized controlled trials with a total of 1069 patients. Our analysis showed that at 6 months postinjection, PRP and hyaluronic acid (HA) had similar effects with respect to pain relief (WOMAC pain score) and functional improvement (WOMAC function score, WOMAC total score, International Knee Documentation Committee score, Lequesne score). At 12 months postinjection, however, PRP was associated with significantly better pain relief (WOMAC pain score, mean difference -2.83, 95% confidence interval [CI] -4.26 to -1.39, P = .0001) and functional improvement (WOMAC function score, mean difference -12.53, 95% CI -14.58 to -10.47, P  < .00001; WOMAC total score, International Knee Documentation Committee score, Lequesne score, standardized mean difference 1.05, 95% CI 0.21-1.89, P = .01) than HA, and the effect sizes of WOMAC pain and function scores at 12 months exceeded the MCID (-0.79 for WOMAC pain and -2.85 for WOMAC function score). Compared with saline, PRP was more effective for pain relief (WOMAC pain score) and functional improvement (WOMAC function score) at 6 months and 12 months postinjection, and the effect sizes of WOMAC pain and function scores at 6 months and 12 months exceeded the MCID. We also found that PRP did not increase the risk of adverse events compared with HA and saline. CONCLUSIONS: Current evidence indicates that, compared with HA and saline, intra-articular PRP injection may have more benefit in pain relief and functional improvement in patients with symptomatic knee OA at 1 year postinjection. LEVEL OF EVIDENCE: Level I, meta-analysis of Level I studies.


Subject(s)
Osteoarthritis, Knee/therapy , Platelet-Rich Plasma , Humans , Hyaluronic Acid/therapeutic use , Injections, Intra-Articular , Pain Measurement , Randomized Controlled Trials as Topic , Viscosupplements/therapeutic use
8.
Biomed Res Int ; 2016: 9480539, 2016.
Article in English | MEDLINE | ID: mdl-27525282

ABSTRACT

Background. Laparoscopic cholecystectomy is usually carried out under general anesthesia. There were a few studies which have found spinal anesthesia as a safe alternative. We aimed to evaluate the postoperative events between spinal anesthesia and general anesthesia in patients undergoing laparoscopic cholecystectomy. Methods. We searched PubMed, Embase, and Cochrane Library (from inception to January 2016) for eligible studies. The primary outcome was the visual analogue scale score. Secondary outcomes included postoperative nausea and vomiting and urine retention 24 hours postoperatively. We calculated pooled risk ratios and 95% confidence interval using random- or fixed-effects models. Results. Eight trials involving 723 patients were listed. Meta-analysis showed that patients in spinal anesthesia groups have lower visual analogue scale score 24 hours postoperatively. There were significant decreases in the occurrence of postoperative nausea and vomiting in spinal anesthesia group when compared with general anesthesia group (odds ratios: 0.38, 95% confidence interval: 0.19-0.76; P = 0.006) with heterogeneity accepted (I (2) = 13%; P = 0.33), while urine retention rate was increased in patients with spinal anesthesia (odds ratios: 4.95, 95% confidence interval: 1.24-19.71; P = 0.02) without any heterogeneity (I (2) = 0%; P = 0.98). Conclusions. Spinal anesthesia may be associated with less postoperative pain and postoperative nausea and vomiting compared with general anesthesia.


Subject(s)
Anesthesia, General/statistics & numerical data , Anesthesia, Spinal/statistics & numerical data , Cholecystectomy, Laparoscopic/statistics & numerical data , Pain, Postoperative/epidemiology , Postoperative Nausea and Vomiting/epidemiology , Urinary Retention/epidemiology , Adult , Age Distribution , Causality , Comorbidity , Female , Gallbladder Diseases/epidemiology , Gallbladder Diseases/surgery , Humans , Male , Pain, Postoperative/prevention & control , Postoperative Nausea and Vomiting/prevention & control , Randomized Controlled Trials as Topic , Risk Factors , Sex Distribution , Treatment Outcome , Urinary Retention/prevention & control
9.
Environ Geochem Health ; 38(5): 1169-1181, 2016 Oct.
Article in English | MEDLINE | ID: mdl-26563207

ABSTRACT

Mining activities are among the major culprits of the wide occurrences of soil and water pollution by PAHs in coal district, which have resulted in ecological fragilities and health risk for local residents. Sixteen PAHs in multimedia environment from the Heshan coal district of Guangxi, South China, were measured, aiming to investigate the contamination level, distribution and possible sources and to estimate the potential health risks of PAHs. The average concentrations of 16 PAHs in the coal, coal gangue, soil, surface water and groundwater were 5114.56, 4551.10, 1280.12 ng g(-1), 426.98 and 381.20 ng L(-1), respectively. Additionally, higher soil and water PAH concentrations were detected in the vicinities of coal or coal gangue dump. Composition analysis, isomeric ratio, Pearson correlation analysis and principal component analysis were performed to diagnose the potential sources of PAHs in different environmental matrices, suggesting the dominant inputs of PAHs from coal/coal combustion and coal gangue in the soil and water. Soil and water guidelines and the incremental lifetime risk (ICLR) were used to assess the health risk, showing that soil and water were heavily contaminated by PAHs, and mean ICLRcoal/coal-gangue and mean ICLRsoil were both significantly higher than the acceptable levels (1 × 10(-4)), posing high potential carcinogenic risk to residents, especially coal workers. This study highlights the environmental pollution problems and public health concerns of coal mining, particularly the potential occupational health hazards of coal miners exposed in Heshan.


Subject(s)
Coal Mining , Polycyclic Aromatic Hydrocarbons/analysis , Risk Assessment , Soil Pollutants/analysis , Water Pollutants, Chemical/analysis , Carcinogens/analysis , China , Coal/analysis , Environmental Monitoring/methods , Humans , Miners
10.
BMC Anesthesiol ; 15: 118, 2015 Aug 15.
Article in English | MEDLINE | ID: mdl-26276641

ABSTRACT

BACKGROUND: Dexamethasone is an antiemetic alternative to ondansetron. We aimed to compare the effects of dexamethasone and ondansetron in preventing postoperative nausea and vomiting (PONV) in patients undergoing laparoscopic surgery. METHODS: We searched PubMed, Embase, Medline and Cochrane Library (from inception to July 2014) for eligible studies. The primary outcome was the incidence of PONV during the first 24 h after surgery. The secondary outcomes included PONV in the early postoperative stage (0-6 h), PONV in the late postoperative stage (6-24 h), and the postoperative anti-emetics used at both stages. We calculated pooled risk ratios (RR) and 95 % CIs using random- and fixed-effects models. RESULTS: Seven trials involving 608 patients were included in this meta-analysis, which found that dexamethasone had a comparable effectiveness in preventing PONV (RR, 0.91; 95 % CI, 0.73-1.13; P = 0.39) with that of ondansetron within 24 h of laparoscopic surgery, with no evidence of heterogeneity among the studies (I(2) = 0 %; P = 0.71). In the early postoperative stage (0-6 h), ondansetron was better at decreasing PONV than dexamethasone (RR, 1.71; 95 % CI, 1.05-2.77; P = 0.03), while in the late postoperative stage (6-24 h), dexamethasone was more effective in preventing PONV than ondansetron (RR, 0.51; 95 % CI, 0.27-0.93; P = 0.03). There was no significant difference in the postoperative anti-emetics used (RR, 0.90; 95 % CI, 0.67-1.19; P = 0.45). CONCLUSIONS: Dexamethasone was as effective and as safe as ondansetron in preventing PONV. Dexamethasone should be encouraged as an alternative to ondansetron for preventing PONV in patients undergoing laparoscopic surgery.


Subject(s)
Antiemetics/therapeutic use , Dexamethasone/therapeutic use , Laparoscopy/statistics & numerical data , Ondansetron/therapeutic use , Postoperative Nausea and Vomiting/prevention & control , Randomized Controlled Trials as Topic/statistics & numerical data , Humans , Treatment Outcome
12.
ScientificWorldJournal ; 2014: 514736, 2014.
Article in English | MEDLINE | ID: mdl-25202727

ABSTRACT

The Tibetan Plateau is regarded as one of the most climatic-sensitive regions all over the world. Long-term remote sensing data enable us to monitor spatial-temporal change in this area. The vegetation changes of the western Nyainqentanglha region were detected by using RS and GIS techniques. And the vegetation coverage was derived by the NDVI-SMA (spectral mixture analysis) methods. An incensement of vegetation was observed in the mountain areas during 1972-2009 with a mean vegetation coverage of 24.87%, 35.89%, and 42.88% in 30/09/1972, 14/09/1991, and 30/08/2009, respectively. The vegetation fraction increased by 18% in the period of 1972-2009. The bin with the elevation between 4400 and 5200 m had the highest vegetation coverage. This may be the result of the mountain effect. Alpine vegetation had a trend to increase and expand to higher altitudes with the climate change in the past 40 years. The variation appears to be associated with an increase in mean temperature of 0.05 °C per year and an increase in precipitation of 1.83 mm per year in the growing season of the past four decades. The results provide further evidence of alpine ecosystem change due to climate change in the central Tibetan Plateau.


Subject(s)
Altitude , Climate Change , Cold Temperature , Ecosystem , China , Geography
13.
Molecules ; 17(1): 716-27, 2012 Jan 12.
Article in English | MEDLINE | ID: mdl-22241467

ABSTRACT

In this study, we evaluated effect of glycyrrhizin on immunity function in allergic rhinitis (AR) mice. The AR mice model were induced by dripping ovalbumin in physiological saline (2 mg mL⁻¹, 10 µL) into the bilateral nasal cavities using a micropipette. After the AR model was induced, mice were randomly divided into six groups: the normal control, model, lycopene 20 mg kg⁻¹ (as positive control drug) group, and glycyrrhizin 10, 20, 30 mg kg⁻¹ groups. After the sensitization day 14, lycopene (20 mg/kg BW) and glycyrrhizin (10, 20 and 30 mg/kg BW) were given orally for 20 days once a day. Mice in the normal control and model groups were given saline orally once a day for 20 days. Results showed that glycyrrhizin treatment could dose-dependently significantly reduce blood immunoglobulin E (IgE), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), nitrous oxide (NO), tumor necrosis factor-alpha (TNF-α) levels and nitrous oxide synthase (NOS) activity and enhance blood immunoglobulin A (IgA), immunoglobulin G (IgG), immunoglobulin M (IgM), interleukin-2 (IL-2) and interleukin-12 (IL-12) levels in AR mice. Furthermore, glycyrrhizin treatment could dose-dependently significantly enhance acetylcholinesterase (AchE) activity and reduce substance P (SP) level in peripheral blood and nasal mucosa of AR mice. We conclude that glycyrrhizin can improve immunity function in AR mice, suggesting a potential drug for the prevention and therapy of AR.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Glycyrrhizic Acid/pharmacology , Rhinitis, Allergic, Perennial/immunology , Acetylcholinesterase/metabolism , Animals , Anti-Inflammatory Agents/therapeutic use , Glycyrrhizic Acid/therapeutic use , Immunoglobulins/blood , Interleukins/blood , Male , Mice , Nasal Mucosa/drug effects , Nasal Mucosa/enzymology , Nasal Mucosa/metabolism , Nitric Oxide/blood , Nitric Oxide Synthase/blood , Ovalbumin , Random Allocation , Rats , Rhinitis, Allergic, Perennial/blood , Rhinitis, Allergic, Perennial/chemically induced , Rhinitis, Allergic, Perennial/drug therapy , Substance P/blood , Substance P/metabolism , Tumor Necrosis Factor-alpha/blood
14.
Int J Mol Sci ; 12(2): 905-16, 2011 Jan 26.
Article in English | MEDLINE | ID: mdl-21541033

ABSTRACT

Oxidative stress is considered as a major risk factor that contributes to increased lipid peroxidation and declined antioxidants in some degenerative diseases. Glycyrrhizin is widely used to cure allergic diseases due to its medicinal properties. In the present study, we evaluated the role of glycyrrhizin on lipid peroxidation and antioxidant status in the blood and nasal mucosa of allergic rhinitis (AR) mice. Mice were divided into six groups: normal control mice, model control (MC) mice, three glycyrrhizin-treated mice groups and lycopene-treated mice. Sensitization-associated increase in lipid peroxidation was observed in the blood and nasal mucosa of MC mice. Activities of antioxidant enzymes like superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), total antioxidant capacity (TAOC) and levels of glutathione (GSH) were found to be significantly decreased in the blood and nasal mucosa in MC mice when compared to normal control mice. However, normalized lipid peroxidation and antioxidant defenses were reported in the glycyrrhizin-treated and lycopene-treated mice. Moreover, glycyrrhizin treatment still enhanced IFN-γ and reduced IL-4 levels in glycyrrhizin-treated mice. These findings demonstrated that glycyrrhizin treatment enhanced the antioxidant status and decreased the incidence of free radical-induced lipid peroxidation and improved immunity activities in the blood and nasal mucosa of AR mice.


Subject(s)
Antioxidants/therapeutic use , Glycyrrhizic Acid/therapeutic use , Rhinitis, Allergic/metabolism , Animals , Carotenoids/therapeutic use , Catalase/blood , Catalase/metabolism , Glutathione/blood , Glutathione/metabolism , Glutathione Peroxidase/blood , Glutathione Peroxidase/metabolism , Interferon-gamma/blood , Interleukin-4/blood , Lipid Peroxidation , Lycopene , Mice , Nasal Mucosa/drug effects , Nasal Mucosa/immunology , Nasal Mucosa/metabolism , Rhinitis, Allergic/drug therapy , Rhinitis, Allergic/immunology , Superoxide Dismutase/blood , Superoxide Dismutase/metabolism
15.
Article in Chinese | MEDLINE | ID: mdl-18414706

ABSTRACT

OBJECTIVE: To prepare monoclonal antibody (mAb) against prM epitope. METHODS: The gene encoding prM was isolated using RT-PCR from brain of JEV infected mouse and cloned into prokaryotic expression vector pET-32a. Recombinant plasmid was transformed into E.coli BL21/DE3/LysS, then the transformed cells were expressed with the induction of IPTG. The expression and purification of the prM protein was analyzed by SDS-PAGE. The BALB/c mice were immunized with purified prM protein. Hybridoma cell lines secreting monoclonal antibodies against prM were established after cell fusion of mouse splenic cell and P3-X63-Ag8.653 cells. The specificity of mAb was identified by ELISA, Western Blot and Immunohistochemistry assay. RESULTS: mAb against prM epitope of JEV was prepared successfully. CONCLUSION: The obtained prM specific mAb was valuable for the prevention and dignosis of Japanese encephalitis.


Subject(s)
Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/isolation & purification , Encephalitis Virus, Japanese , Prokaryotic Cells/metabolism , Viral Proteins/biosynthesis , Viral Proteins/isolation & purification , Animals , Antibodies, Monoclonal/analysis , Antibody Specificity , BALB 3T3 Cells , Cell Line , Cloning, Molecular , Electrophoresis, Polyacrylamide Gel , Encephalitis Virus, Japanese/genetics , Encephalitis Virus, Japanese/immunology , Epitopes/immunology , Escherichia coli/genetics , Mice , Plasmids/genetics , Plasmids/metabolism , Sequence Analysis, DNA , Viral Proteins/genetics , Viral Proteins/immunology
16.
Article in Chinese | MEDLINE | ID: mdl-15597705

ABSTRACT

OBJECTIVE: To clone, sequence, and express the aldolase (ALD) encoding gene of Plasmodium falciparum FCC1/HN strain. METHODS: The ALD encoding gene was amplified by PCR from genomic DNA of FCC1/HN strain. The positive clones were screened and identified by agarose gel electrophoresis and endonuclease. The recombinant plasmid was transformed into E. coli M15. The fusion protein was expressed by IPTG induction and purified by Ni-NTA affinity chromatography and anion exchange column. RESULTS: The ALD gene of P. falciparum was amplified. Analysis of sequencing showed that the ALD gene of P. falciparum was identical with the sequence of other reported isolates. A Mr 41,000 fusion protein was induced by IPTG and was purified by chromatography. CONCLUSION: The ALD gene of P. falciparum FCC1/HN strain was identical to the other reported isolates. ALD fusion protein of P. falciparum was expressed and purified.


Subject(s)
Fructose-Bisphosphate Aldolase/genetics , Plasmodium falciparum/enzymology , Plasmodium falciparum/genetics , Recombinant Fusion Proteins/biosynthesis , Amino Acid Sequence , Animals , Cloning, Molecular , Escherichia coli/genetics , Escherichia coli/metabolism , Fructose-Bisphosphate Aldolase/biosynthesis , Molecular Sequence Data , Plasmodium falciparum/classification , Polymerase Chain Reaction , Recombinant Fusion Proteins/genetics , Transformation, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL
...